Provided by Tiger Trade Technology Pte. Ltd.

HANSOH PHARMA

35.300
+1.7805.31%
Volume:13.13M
Turnover:457.36M
Market Cap:214.06B
PE:32.50
High:35.420
Open:33.200
Low:33.200
Close:33.520
52wk High:43.587
52wk Low:27.658
Shares:6.06B
HK Float Shares:6.06B
Volume Ratio:2.05
T/O Rate:0.22%
Dividend:0.49
Dividend Rate:1.40%
EPS(LYR):1.086
ROE:19.40%
ROA:9.08%
PB:4.85
PE(LYR):32.50
PS:11.53

Loading ...

Hansoh Pharma's Osteosarcoma Therapy Gains NMPA Priority Review Designation

Stock News
·
Sep 22

Hansoh Pharmaceutical - Risvutatug Rezetecan for Injection Included in Nmpa Priority Review for Osteosarcoma

THOMSON REUTERS
·
Sep 22

Hansoh Pharma's Novel Autoimmune Drug Meets Phase 3 Goals, Sets Sights on Regulatory Submission

Deep News
·
Sep 21

Hansoh Pharmaceutical Group Stock Rises 3.7% in Hong Kong

Dow Jones
·
Sep 21

Hansoh Rises on Positive Clinical Trial Results for Plaque Psoriasis Drug

Reuters
·
Sep 21

Movement Alert|HANSOH PHARMA Rises 3.03% in Regular Trading, TYK2 Inhibitor HS-10374 Hits Phase III Primary Endpoints in Psoriasis Trial

Market Focus
·
Sep 21

Hansoh Pharma Says Phase 3 HS-10374 Psoriasis Trial Meets Co-Primary Endpoints

Reuters
·
Sep 21

Hansoh Pharmaceutical - Hs-10374 Meets Co-Primary Endpoints in Phase Iii Plaque Psoriasis Trial

THOMSON REUTERS
·
Sep 21

Movement Alert|HANSOH PHARMA Rises 3.09% in Regular Trading, New Drug HS-20197 Approved for Clinical Trials Targeting Solid Tumors

Market Focus
·
Sep 18

Hansoh Pharmaceutical Group Stock Climbs 1.0% in Hong Kong

Dow Jones
·
Sep 17

Hansoh Pharma Gets China Approval for Solid Tumor Drug Trials

MT Newswires Live
·
Sep 16

Hansoh Pharmaceutical - Hs-20197 for Injection Receives Clinical Trial Approval from Nmpa of China

THOMSON REUTERS
·
Sep 16

UBS Highlights Encouraging Phase 3 Data for Hansoh Pharma's Ris-Rez in Relapsed Small Cell Lung Cancer, Maintains "Buy" Rating

Stock News
·
Sep 15

Roche, GSK's Lung-Cancer Drug Candidates Show Promise in China

Dow Jones
·
Sep 14

AI Concerns, Oil Bills Blunt Asian Stock Markets

MT Newswires Live
·
Sep 14

Hansoh Pharma Reports 81.5% Response Rate in Phase Ib HS-10370 Combo Trial in First-Line KRAS G12C NSCLC

Reuters
·
Sep 14

Hansoh Pharmaceutical Group Stock Rises 5.1% in Hong Kong

Dow Jones
·
Sep 14

GSK Gains After Positive Results for Two Lung Cancer Drugs

Reuters
·
Sep 14

JPMorgan Highlights Encouraging Lung Cancer Data for Hansoh Pharma's B7-H3 ADC, Reaffirms Overweight Rating

Stock News
·
Sep 14

HK Stock Alert: Hansoh Pharma Climbs Nearly 4%; Drug Trial Shows Median Survival of 18.5 Months

Stock News
·
Sep 14